Get started
Sutro Biopharma, Inc.Sutro Biopharma, Inc.Sutro Biopharma, Inc.

Sutro Biopharma, Inc.

No trades
See on Supercharts
Overview
Financials News Ideas Discussions Technicals Forecast Seasonals Options

STRO chart


Full chart

STRO upcoming earnings


Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—

Key stats


Market capitalization
‪46.59 M‬ USD
Dividend yield (indicated)
—
Price to earnings Ratio (TTM)
—
Basic EPS (TTM)
−3.0108 USD
Net income (FY)
‪−227.46 M‬ USD
Revenue (FY)
‪62.04 M‬ USD
Shares float
‪76.02 M‬
Beta (1Y)
3.51

Employees


Employees (FY)
338
Change (1Y)
+36 +11.92%
Revenue / Employee (1Y)
‪183.56 K‬ USD
Net income / Employee (1Y)
‪−672.96 K‬ USD

About Sutro Biopharma, Inc.


Sector
Health Technology
Industry
Pharmaceuticals: Major
CEO
Jane Chung
Website
sutrobio.com
Headquarters
South San Francisco
Founded
2003
FIGI
BBG000R4V3P3
Sutro Biopharma, Inc. engages in the drug discovery, development and manufacture of pharmaceutical products. It focuses on the next generation cancer and autoimmune therapeutics. The company was founded by James R. Swartz and Sutanto Widjaja on April 21, 2003 and is headquartered in South San Francisco, CA.

Financials


Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:—

STRO news



Ideas



See all ideas 

Technicals


Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Analyst rating


An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Seasonals


Displays a symbol's price movements over previous years to identify recurring trends.

Check out other big names from the same industry as STRO.

Frequently Asked Questions


The current price of STRO is 0.7248 USD — it has increased by 21.73% in the past 24 hours. Watch Sutro Biopharma, Inc. stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange Sutro Biopharma, Inc. stocks are traded under the ticker STRO.
STRO stock has risen by 12.05% compared to the previous week, the month change is a −14.90% fall, over the last year Sutro Biopharma, Inc. has showed a −80.25% decrease.
We've gathered analysts' opinions on Sutro Biopharma, Inc. future price: according to them, STRO price has a max estimate of 17.00 USD and a min estimate of 1.00 USD. Watch STRO chart and read a more detailed Sutro Biopharma, Inc. stock forecast: see what analysts think of Sutro Biopharma, Inc. and suggest that you do with its stocks.
STRO reached its all-time high on Feb 8, 2021 with the price of 28.3000 USD, and its all-time low was 0.5231 USD and was reached on Apr 17, 2025. View more price dynamics on STRO chart.
See other stocks reaching their highest and lowest prices.
STRO stock is 40.46% volatile and has beta coefficient of 3.51. Track Sutro Biopharma, Inc. stock price on the chart and check out the list of the most volatile stocks — is Sutro Biopharma, Inc. there?
Today Sutro Biopharma, Inc. has the market capitalization of ‪61.15 M‬, it has decreased by −7.06% over the last week.
Yes, you can track Sutro Biopharma, Inc. financials in yearly and quarterly reports right on TradingView.
Sutro Biopharma, Inc. is going to release the next earnings report on May 19, 2025. Keep track of upcoming events with our Earnings Calendar.
STRO earnings for the last quarter are −0.83 USD per share, whereas the estimation was −0.83 USD resulting in a 0.049% surprise. The estimated earnings for the next quarter are −0.64 USD per share. See more details about Sutro Biopharma, Inc. earnings.
Sutro Biopharma, Inc. revenue for the last quarter amounts to ‪14.80 M‬ USD, despite the estimated figure of ‪12.15 M‬ USD. In the next quarter, revenue is expected to reach ‪11.61 M‬ USD.
STRO net income for the last quarter is ‪−72.44 M‬ USD, while the quarter before that showed ‪−48.79 M‬ USD of net income which accounts for −48.49% change. Track more Sutro Biopharma, Inc. financial stats to get the full picture.
No, STRO doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Apr 23, 2025, the company has 338 employees. See our rating of the largest employees — is Sutro Biopharma, Inc. on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. Sutro Biopharma, Inc. EBITDA is ‪−231.24 M‬ USD, and current EBITDA margin is −372.70%. See more stats in Sutro Biopharma, Inc. financial statements.
Like other stocks, STRO shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Sutro Biopharma, Inc. stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Sutro Biopharma, Inc. technincal analysis shows the neutral today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Sutro Biopharma, Inc. stock shows the sell signal. See more of Sutro Biopharma, Inc. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.